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Abstract 26 
BACKGROUND:  A common assertion is that rating scale (RS) values are lower than both 27 
standard gamble (SG) and time tradeoff (TTO) values. However, differences among these 28 
methods may be due to method specific bias.  While SG and TTO suffer systematic bias, RS 29 
responses are known to depend on the range and frequency of other health states being evaluated.  30 
Over many diverse studies this effect is predicted to diminish.  Thus, a systematic review and data 31 
synthesis of RS-TTO and RS-SG difference scores may better reveal persistent dissimilarities.   32 
PURPOSE: To establish through systematic review and meta-analysis the net effect of biases that 33 
endure over many studies of utilities.   34 
PARTICIPANTS:  2,206 RS and TTO and 1,318 RS and SG respondents in 27 studies of utilities.  35 
DATA SOURCE:  MEDLINE search from 1976 to 2004, complemented by a hand search of full 36 
length articles and conference abstracts for nine journals known to publish utility studies, as well 37 
as review of results and additional recommendations by five outside experts in the field.   38 
DATA EXTRACTION:  Two investigators abstracted the articles.  We contacted the 39 
investigators of the original if required information was not available.  40 
DATA SYNTHESIS:  No significant effect for RS and TTO difference scores was observed:  41 
effect size (95% C.I.) = 0.04 (-0.02, 0.09).  In contrast, RS scores were significantly lower than 42 
SG scores:  Effect size (95% C.I.) = -0.23 (-.28, -0.19).  Correcting SG scores for three known 43 
biases (loss aversion, framing and probability weighting) eliminated differences between RS and 44 
SG scores (effect size (95% C.I.) = 0.01 (-0.03, 0.05).  45 
LIMITATIONS:  Systematic bias in the RS method may exist but be heretofore unknown.  Bias 46 
correction formulas were applied to mean not individual utilities.   47 
CONCLUSIONS:  The results of this paper do not support the common view that RS values are 48 
lower than TTO values, may suggest that TTO biases largely cancel, and support the validity of 49 
formulas for correcting standard gamble bias. 50 
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Introduction 51 
The purpose of this paper is to establish through systematic review and meta-analysis the 52 
net effect of health utility biases that occur under different elicitation methods.  Health utilities 53 
play an important role in cost-effectiveness analysis.  Through health utility assessment, to each 54 
health state in the analysis a presumably unique quality weight is assigned. The standard gamble 55 
(SG), time tradeoff (TTO) and rating scale (RS) are the most common preference assessment 56 
methods for assigning such weights.  However, when more than one elicitation method is 57 
employed it is often the case that more than one quality weight may be assigned to any particular 58 
health state [1, 2].  One negative implication of this is that treatment recommendations may be 59 
sensitive to the method of preference assessment [3].  Differences among health state valuation 60 
methods may be due to biases that lead to errors in measurement and result in health state utilities 61 
that are too high or too low.   By seeking to understand the net effect of bias we may be in a better 62 
position to recommend certain methods that minimize the occurrence of errors. 63 
Errors that affect measurement may be divided into two classes:  1) systematic error -   64 
misestimation of a measurement value that is persistent both in direction and magnitude, and, 2) 65 
nonsystematic error – misestimation of a measurement value that is variable in magnitude and 66 
direction.  Over many observations, systematic error endures and nonsystematic error abates.  We 67 
capitalize on this fact, to study within a met-analytic framework the net effect of health utility 68 
bias.  As we will explain next, the TTO and the SG are affected by systematic biases and the RS 69 
by nonsystematic biases. Consequently, over many studies the bias in the RS may decrease 70 
whereas the bias in the TTO and the SG remains. By pooling the results from many studies the 71 
comparison of the TTO and the SG with the RS can, therefore, give insight in the direction of the 72 
bias in the TTO and the SG. It is important to emphasize that we do not claim that the RS is the 73 
gold standard in health utility measurement. Any single RS measurement will be affected by 74 
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biases. Our point is that over many studies these biases will be reduced and this property provides 75 
a benchmark with which to compare the TTO and the SG. 76 
Systematic Error in Health State Valuations 77 
The TTO and SG methods are susceptible to several known effects that lead to persistent, or 78 
systematic, errors.  These effects are:  Loss aversion, scale compatibility, utility curvature over 79 
life duration and probability weighting.  A review of these effects is beyond the scope of this 80 
paper and can be found elsewhere (see Bleichrodt [4] for review).  These biases alter scores such 81 
that they deviate from a value that best characterizes preference for a health state, thus making 82 
scores too high or too low.  They generally increase SG scores, have both upward and downward 83 
effects on TTO scores and are predicted to have no effect on RS scores.  Table 1 provides a 84 
summary of the aforementioned known predominantly upward (+) and downward (-) causes of 85 
systematic error in SG, TTO and RS values.   86 
------------------------------------------------ 87 
INSERT TABLE 1 88 
ABOUT HERE 89 
------------------------------------------------ 90 
Nonsystematic Error in Health State Valuation 91 
While the RS method is not susceptible to known systematic biases, individual 92 
observations are well-known to be influenced by nonsystematic error resulting from contextual 93 
bias.  With the RS method, the respondent’s task is to assign categories (typically integer 94 
numbers) to health state stimuli such that succeeding categories represent equal steps in value.  95 
However, empirical research has demonstrated that characteristics of an RS response depend on 96 
the range and frequency of other health states being rated [5, 6, 7].   Figure 1 illustrates range and 97 
frequency effects for a health state with bias free health state value of 0.40.   98 
------------------------------------------------ 99 
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INSERT FIGURE 1 100 
ABOUT HERE 101 
------------------------------------------------ 102 
In each panel the x-axis represents bias free value and the y-axis denotes observed value.  103 
In the left panel, labeled “Range Effect”, one group of respondents rated the health state in 104 
context (C1) which includes a limited range of health state values (range = 0.30 to 0.70).  Because 105 
of a desire to spread responses over the full range of the response scale, the observed rating 106 
differs in C1 than for subjects whose ratings were made in context C2, a context with a broader 107 
range of health state values (0.0 – 1.0).  In the right panel, labeled “Frequency Effect”, the health 108 
state is presented either amongst a set of health states where a preponderance have either low 109 
subjective value (C3), or, high subjective value (C4).  By the frequency effect, observed rating 110 
response is more sensitive to changes in value when most stimuli are of similar value to the state 111 
being evaluated.  An important point is that range and frequency effects produce error magnitude 112 
and direction that is specific to context; hence error is not systematic but changes with context. 113 
Schwartz [8] applied range-frequency theory to explain with great precision contextual bias in RS 114 
scores reported elsewhere [5].  Robinson et al. [6] confirmed this finding in a separate 115 
experiment.  Pollack [9, 10] demonstrated convincingly that rating scales could be unbiased when 116 
contextual factors were varied iteratively over many experiments i.e., Pollack [9, 10]  identified 117 
and subsequently manipulated bias effects to neutralize bias.  The nonsystematic nature of rating 118 
scale context bias suggests that over many naturally occurring studies rating scale bias may 119 
decrease in size.  120 
Whether or not SG or TTO values are influenced by nonsystematic factors like context 121 
has received much less attention.  Robinson et al. [6] found in a context manipulation experiment 122 
that SG values were much less susceptible to context effects than were RS values.  We are 123 
unaware of any studies examining context effects and TTO responses. 124 
Comparing RS, TTO and SG Values 125 
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Empirically, RS, TTO and SG values do not appear to agree. A common assertion is that 126 
RS values are lower than TTO and SG values [1, 2].  However, given that the RS is subject to a 127 
context bias, one may not conclude from any single study, that RS values are lower or higher than 128 
TTO or SG values.  This caveat applies even when no explicit context is given, in particular, 129 
when respondents rate only their current health.  Birnbaum [11] has shown that when not given 130 
an explicit context, respondents choose their own contexts and choose different ones for different 131 
stimuli.  He was in fact able to show through a between-subjects experiment that the number “9” 132 
achieved a higher largeness rating than the number “221”.  Presumably, “9” is large in the context 133 
of one digit numbers and “221” is small in the context of three digit numbers.  Such an effect 134 
appears not easily alleviated by explicit use of anchors at points along the rating scale [11,12]. 135 
Hence, conclusions about relative value differences between TTO (or SG) and RS drawn from 136 
data collected within any single study where not every respondent rated the same health states are 137 
also not likely trustworthy.  Only by comparing RS values against TTO (or SG) values in explicit 138 
contexts, across many studies and administered within-subject is it likely that context effects will 139 
diminish.  In this paper, using a meta-analytic approach, we address the question of the overall 140 
effect of bias on TTO and SG scores.  We capitalize on the fact that while the TTO and SG are 141 
susceptible to biases that result in systematic error in health state value, another method, the 142 
rating scale (RS) is susceptible to contextual effects that are nonsystematic across studies. Hence, 143 
while nonsystematic error diminishes when rating scale data are aggregated over many studies, 144 
systematic TTO and SG method error should persist. 145 
Methods 146 
Search Strategy and Inclusion Criteria 147 
We searched (with no language restrictions) for all reports where RS and the TTO measures, or, 148 
SG and TTO measures were given to the same subjects evaluating the same health state at any 149 
one measurement interval. We performed a MEDLINE search using the following queries in all 150 
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fields:  1) (rating scale OR category scale OR visual analogue scale 151 
OR visual analog scale) AND (time tradeoff OR time trade-off), and 152 
2) (category scale OR rating scale OR visual analogue scale OR 153 
visual analog scale) AND standard gamble.  These searches were thought to be 154 
general enough to contain, as a smaller subset, as many studies as possible within our inclusion 155 
criteria (listed below).  The search period was January 1st of 1976 through December 31st of 2004. 156 
We also completed a second manual search of 9 journals that are well-known to publish health 157 
utility data (see Table 2).  158 
--------------------------------------------------- 159 
INSERT TABLE 2 160 
ABOUT HERE 161 
--------------------------------------------------- 162 
This second search was conducted to: 1) identify articles possibly missed by the MEDLINE 163 
search and, 2) extract results from abstracts published from conference proceedings printed in a 164 
subset of the journals listed in Table 2. The latter was done to avoid publication bias.  When 165 
findings reported in an abstract were later published as a full-length article, only the data from the 166 
full length article were used in the meta-analysis.  We complemented our search by reviewing the 167 
reference lists from original research and review articles.   Finally, we circulated the list of studies 168 
we found to five experts in the field to see whether they could come up with more studies.  169 
Experts were included if they had been a lead or senior author on a paper found on the list 170 
generated by our search methods.  Four experts accepted and one declined on the grounds that she 171 
had not worked in the area for some time.  The expert who declined did recommend a well-172 
known replacement who agreed to serve as the fifth expert. 173 
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Inclusion criteria were: 1) studies that elicited, for the same set of subjects, multiple methods of 174 
utility assessment, 2) multiple methods had to include the RS method along with either the SG or 175 
TTO methods, 3) all subjects had to receive the same health state descriptions, 4) reported utility 176 
scores had to be elicited, and could not be predicted from formulas or multi-attribute 177 
questionnaires (e.g., EQ-5D, Health Utilities Index, or Quality of Well-Being Scale), and 5) for 178 
TTO studies duration in current health had to exceed 5 years due to a documented unwillingness 179 
to trade time over short durations [13].  After consultation with experts a fifth inclusion criteria 180 
was added:  Health states had to be evaluated by respondents as “better than death”.  Studies that 181 
did not meet the inclusion criteria were excluded.  We note that by our third criterion, health state 182 
descriptions had to be hypothetical and could not reflect an individual’s unique current health 183 
description; nor could the health state choice set be manipulated in a between-subjects 184 
experiment. 185 
  We contacted the investigators of the original studies if information was required to establish 186 
inclusion criteria or information on utility for health state was not available in the published 187 
reports. Missing data that could not be resolved by attempts to contact the authors were median 188 
imputed. Two investigators abstracted the articles. They resolved disagreements by consensus. 189 
Statistical Analysis 190 
Using the rmeta package within the statistical computing language R [14], we conducted two 191 
meta-analyses on effect size data over the aforementioned studies.  The primary meta-analysis 192 
compared within-subject effect sizes for RS and TTO score differences. A secondary meta-193 
analysis compared within-subject effect sizes for RS and SG score differences.  A standard effect-194 
size (d) estimate for within-subject score differences was used [15]: 195 
diff
zRS
DS
MMd
..
−
=  ,   [1] 196 
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 where MRS is the mean RS score, Mz is the mean score for the competing method (either SG or 197 
TTO) and S.D.diff is the standard deviation of the difference scores between the RS and competing 198 
method. In our case, the effect size estimates the average score difference (between two utility 199 
elicitation methods) relative to the variability in task performance in the population.  In order to 200 
compute standard deviation of difference scores, an estimate of the population correlation 201 
between RS and TTO and RS and SG ratings is needed [16].  While several correlation statistics 202 
on these rating methods have been given in the early QALY literature (see [17-19]), Nickerson 203 
[20] has differentiated among several types of correlations between utility elicitation methods and 204 
recommends use of a mean within-respondent correlation in any analysis postulating that 205 
psychological processes affect response (p.494).  Such is the case with our current analysis which 206 
considers that responses are affected by psychological biases. Two papers provide appropriate 207 
(mean within-respondent) correlations for our meta-analytic purposes they are Kartman et al. [21] 208 
and Krabbe et al. [22].  With respect to the mean within-respondent correlation, r, between RS 209 
and TTO scores, Krabbe et al. [22] report this value as r = 0.23, whereas Kartman et al. [21] 210 
report a value of r = 0.25. For this analysis, we report our results under the assumption of the 211 
middle value between these two, r = 0.24.  For the RS and SG difference score meta-analysis, we 212 
report our results under the assumption that r = 0.19. This is half-way between the value reported 213 
by Krabbe et al. [22] r = 0.22, and that of Kartman et al. [21], r = 0.16.  For each analysis we also 214 
ran meta-analyses under the range of standard error assumptions as given by the range of 215 
published correlations between measures.  This was done to determine the robustness of our 216 
findings.  Context bias associated with the rating scale depends on the specific study methods, but 217 
is statistically independent across studies.  Therefore, to preserve this independence assumption 218 
an average effect size computed over utilities elicited for multiple health states within study 219 
served as the dependent variable.   220 
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We chose to conduct random-effects (as opposed to fixed-effects) analyses of data 221 
because rating scale context bias would naturally produce statistically heterogeneous effect sizes 222 
across studies.  The random-effects model incorporates a between study component of variance to 223 
address heterogeneity, whereas a fixed-effects model does not.  An effect size and confidence 224 
interval plot as well is given for the primary analysis. 225 
In addition to analysis on raw standard gambles, we conducted two meta-analyses on 226 
corrected scores.  A correction formula that adjusts for the effects of bias associated with prospect 227 
theory [23] (loss aversion, framing and probability weighting) has been proposed [24] and applied 228 
elsewhere [25]. The first formula we used corrected for only probability weighting [26, 27].   We 229 
applied a one-parameter weighting function as given in Tversky & Kahneman [23] to standard 230 
gamble scores (with the standard assumption that γ = .61 (see p. 309, Equation 6 [23]).  This 231 
gives a standard gamble utility corrected for probability weighting.  The second analysis utilized 232 
the following table [24]: 233 
------------------------------------------------ 234 
INSERT TABLE 3 235 
ABOUT HERE 236 
------------------------------------------------ 237 
In addition to correcting for probability weighting, this table of values corrects for loss 238 
aversion and framing effects.  This table has been used successfully to correct SG bias in other 239 
work [24]. 240 
Finally, an evaluation of study quality was considered.  We evaluated the extent to which 241 
studies we examined adhered to reporting standards for studies of utilities.  Each study received a 242 
quality score based on adherence to ten components of reporting standards given in Table 1 of 243 
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Stalmeier et al. [28].  Quality score was computed as the weighted sum of these ten components 244 
and scaled so that a score of 100 reflected complete adherence and a score of 0 reflected complete 245 
non adherence.  Component weightings were determined by mean expert importance ratings 246 
reported in Stalmeier [28, Table 1 p.206].  We evaluated the correlation of study quality with 247 
effect size, standard error and year of publication.  We also employed quality scores as weights to 248 
determine if this influenced meta-analytic findings. 249 
Results 250 
With regard to the RS and TTO meta-analysis, we identified 4 articles from systematic reviews, 251 
the MEDLINE search yielded 139 results, of these 13 met the inclusion criteria and were not 252 
already identified in the systematic review articles.  An additional 2 studies (conference 253 
presentations) were included from a hand search of the journals in Table 1 and known review 254 
articles.  Experts were not able to identify any additional RS and TTO studies that met our 255 
criteria.  A total of 19 studies were used for the RS and TTO meta-analysis. With respect to the 256 
RS and SG meta-analysis, we identified 7 articles from systematic reviews, the MEDLINE search 257 
yielded 150 results, of these 5 met the inclusion criteria and were not already identified in the 258 
systematic review articles.  An additional 3 studies (conference presentations) were included from 259 
a hand search of the journals in Table 2.  After circulating our list to experts, they were able to 260 
identify one additional study that met our inclusion criteria and which was added.  A total of 16 261 
studies were used for RS – SG meta-analysis.  We note that, as would be expected, studies 262 
utilized in the RS-TTO and RS-SG meta-analyses were not mutually exclusive.  A total of 27 263 
studies were used as data.  Of these studies, eleven collected only RS and TTO responses [29-39], 264 
nine collected only RS and SG responses [40-48] and  seven collected both RS, TTO and SG 265 
responses [17, 19, 49-53]. 266 
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Results indicate no significant effect for RS and TTO difference scores:  effect size (95% 267 
C.I.) = 0.04 (-0.02, 0.09).  Figure 2 shows the plot of confidence intervals centered on effect size 268 
(x-axis) for each study. The “X” indicates an overall effect, the line through it is the confidence 269 
interval.  While there is a small overall effect of 0.04, the confidence interval around this estimate 270 
crosses 0.0.  These results were robust over the range of reported correlations between RS and 271 
TTO values.   272 
------------------------------------------------ 273 
INSERT FIGURE 2 274 
ABOUT HERE 275 
-------------------------------------------- 276 
As mentioned previously, a quality score was determined by the extent to which studies 277 
adhered to published reporting criteria for studies of utility [28].  Adherence was weighted by 278 
published expert ratings of importance [28] and normalized so that a score of 100 indicates total 279 
adherence in reporting and a score of zero indicates total non adherence.  Quality scores for RS-280 
TTO studies ranged between 21.0 and 95.7.  The mean (+ S.D.) importance weighted quality 281 
score for RS-TTO studies was 64.7 (+ 17.9).  An evaluation of Pearson's product-moment 282 
correlations indicated that quality score was not significantly correlated with effect size (r = 0.23, 283 
p = n.s.), standard error (r = -.28, p = n.s.) or year of publication (r = 0.0, p = n.s.).  Adding 284 
quality weights did not significantly influence meta-analytic results in that the confidence interval 285 
for RS–TTO effect size still crossed zero. 286 
In contrast, the meta-analysis on RS and SG values indicated that RS scores were 287 
significantly lower than SG scores:  effect size (95% C.I.) = -0.23 (-.28, -0.19).  These results 288 
were robust to over the range of reported correlations between RS and SG values.  Figure 3 shows 289 
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the plot of confidence intervals centered on effect size estimates (x-axis) for each of the 16 290 
studies included in the analysis.   291 
------------------------------------------------ 292 
INSERT FIGURE 3 293 
ABOUT HERE 294 
------------------------------------------------ 295 
Again, The “X” indicates an overall effect, the line through it is the confidence interval.  296 
The effect is sizeable and the confidence interval around the estimate does not cross zero. 297 
Quality scores for RS-SG studies also ranged between 21.0 and 95.7.  The mean (+ S.D.) 298 
importance weighted quality score for RS-TTO studies was 59.4 (+ 19.3).  An evaluation of 299 
Pearson's product-moment correlations indicated that quality score was not significantly 300 
correlated with effect size (r = 0.22, p = n.s.), standard error (r = -.20, p = n.s.) or year of 301 
publication (r = -0.20, p = n.s.).  Adding quality weights did not significantly influence meta-302 
analytic results in that the confidence interval for RS-SG effect size did not overlap with 0.0 and 303 
registered SG scores as consistently higher than RS scores. 304 
The meta-analyses on corrected standard gamble scores revealed that the probability 305 
weighting correction was effective in reducing SG and RS difference, but left a very small 306 
measurable difference between SG and RS scores (effect size (95% C.I.) = -0.09 (-0.13, -0.05)).  307 
The correction adjusting for loss aversion, framing and probability weighting (see Table 1, p. 308 
1505 in Bleichrodt et al. [24]) eliminated differences altogether, (effect size (95% C.I.) = 0.01 (-309 
0.03, 0.05).  310 
Discussion 311 
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 An early influential review of the health utility field suggested that TTO scores were 312 
higher than RS scores [1].  This assertion was based on the best available data at the time and has 313 
remained largely unchallenged.  However, 15 years later we find that contrary to this notion that 314 
RS scores are lower than TTO scores, RS and TTO scores are about equal when data are 315 
examined systematically over many within-subject studies.  This may indicate that when RS 316 
context bias diminishes, value measurement becomes consistent and TTO and RS values agree.  317 
Another interpretation of this result is that, competing systematic TTO biases may cancel out.  318 
Hence, TTO scores may be relatively unbiased within a study.  In either case, the discrepancy 319 
between our result that TTO and RS agree and the previous result that TTO scores exceed RS 320 
scores is likely due to diminishing RS context bias unique to the meta-analytic approach we used. 321 
In contrast, and as expected, SG biases, which are generally upward, result in higher scores than 322 
when the same individuals rate the same health states using the RS method.  The disparity 323 
between SG and RS disappears when SG scores are corrected for probability weighting, framing 324 
and loss aversion. 325 
There are a few caveats to our results that deserve discussion.  First, it is important to 326 
realize that our results do not suggest that RS and TTO scores are comparable or interchangeable 327 
within a study.  Hence, our study should not be interpreted as offering support for the use of the 328 
RS in economic evaluations of health care. RS scores vary substantially within a study due to 329 
context effects unique to the study.  Our findings show that when evaluated systematically across 330 
many studies, TTO scores do not appear to be higher than RS scores.  We are inclined to interpret 331 
this as evidence that the systematic biases in the TTO tend to cancel. Second, while no systematic 332 
RS biases are known, it is possible that one or more do exist [54], which could threaten the 333 
interpretation that TTO scores overall do not exhibit a directional bias. However, given our 334 
current state of knowledge we can be confident that TTO directional bias is not large in 335 
comparison to the directional bias exhibited by the SG method.  Third, with respect to our 336 
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analysis of standard gamble corrections, the fundamental data element in our study is mean score 337 
for health state; it is not guaranteed that a transformed mean score will equal a mean of 338 
transformed scores.  However, transformed mean scores will approach mean transformed scores 339 
as standard errors approach zero.  In most cases, standard errors were low in the studies we 340 
evaluated. Fourth, other features of elicitation methodologies such as reliability, validity and 341 
responsiveness to change are important but beyond the scope of this paper.   342 
A large body of literature assumes that because the SG is rooted in the axioms of 343 
expected utility theory and is the only scaling method that includes an element of risk inherent in 344 
most medical decisions, the SG represents the reference standard and that other methods (e.g., the 345 
RS) should be adjusted to match SG scores [54].  We do not agree with this point of view. There 346 
is much evidence to suggest that expected utility is not the correct descriptive model (i.e., it may 347 
not characterize observed preference behavior very well).  When decision makers deviate from 348 
expected utility, the SG method will generally yield biased utilities. For this reason, our method 349 
of adjusting scores does not entrust the SG method with preeminence over other methods and 350 
does not relate RS or TTO scores via mapping them to SG as is commonly done.   351 
A basic assumption of this paper is that different methods should produce the same 352 
utilities. A practical rationale for this assumption is that if differences occur then the outcome of 353 
an economic evaluation will depend on the method used.  In the absence of a gold standard for 354 
health utility measurement this is undesirable. Such an assumption is not universally held.  One 355 
theory that became popular in the 1970s and 1980s, contends that risky utility (e.g., SG) and 356 
riskless value (e.g., TTO and RS) may differ by an increasing nonlinear transformation when risk 357 
aversion is considered [55].  In present day, this theory has become less popular for two reasons.  358 
First, it does not permit violations of expected utility theory, which are widely observed [56].  359 
Second, it leads to serious problems in reconciling attitudes toward risk of small and large stakes 360 
losses [57]. For these reasons risk behavior is now primarily modeled, at its source, as attitude 361 
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toward chance (via nonlinear transformation of probabilities) and through the acknowledgement 362 
that decision makers are averse to losses [23]. For an excellent discussion of how this modern 363 
approach moves toward a unified notion of utility, one that has meaning prior to risk and not visa 364 
versa, see Wakker [58]. Empirical studies have shown that when attitude toward chance and loss 365 
aversion are considered, differences between riskless and risky utility tend not to prevail [59, 60, 366 
61].  367 
The findings of this study have implications for cost-effectiveness analysis.  In cost-368 
effectiveness analysis, health utility assessment is carried out so that quality weights can be 369 
assigned to health states in the analysis.  As demonstrated here and elsewhere, methods and 370 
procedures applied to the same health state often result in values that are inconsistent with respect 371 
to each other.  Inconsistencies mean that more than one quality weight can be assigned to any 372 
particular health state.  However, the valid application of CEA requires that one and only one 373 
quality weight be assigned to any particular health state.  The present study is part of a growing 374 
number of studies suggesting that biases that lead to differences between measures can be 375 
reduced or eliminated.  Biases appear to distort preferences in lawful and thus correctable ways, 376 
with corrections yielding greater consistency across methods.  The findings of this paper suggest 377 
that standard gambles may need to be corrected for probability weighting bias.  Loss aversion and 378 
framing effects may also be of concern with the standard gamble.  In contrast, the findings of this 379 
paper do not support a net directional systematic TTO bias and give further support to the use of 380 
raw TTO values in cost-effectiveness analysis.  Finally, while RS contextual bias may diminish 381 
over many studies, unless contextual bias is manipulated and neutralized within an experiment it 382 
is likely to adversely influence ratings in individual studies.383 
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Table 1.  Known predominantly upward (+) and downward (-) causes of systematic error in SG, 599 
TTO and RS values 600 
 601 
Type of Effect SG  TTO RS 
Loss Aversion + + No Effect 
Scale Compatibility Ambiguous + No Effect 
Utility Curvature No Effect - No Effect 
Probability weighting +  No Effect No Effect 
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Table 2.  Journals searched by hand for full-length articles and or conference abstracts possibly 602 
missed by MEDLINE search 603 
 604 
Journal Title Search Interval 
Health Economics 1984 - 2002 
Health Policy 1984 – 1989 
Health Policy in Amersterdam and Netherland 1989 – 2000 
International Journal of Technology 
Assessment in Health Care 
1985 – Present 
Journal of Health Economics: 1984 – 2002 
Medical Care 1978 – Present 
Medical Decision Making 1981 – Present 
Quality of Life Research 1993 – Present 
Pharmacoeconomics 1992 – Present 
 605 
Table 3.  Corrected standard gamble utilities as proposed by Bleichrodt et al. [24] for standard gamble elicitations between 0.00 and 0.99.  Row 606 
headings represent tenths, column headings hundredths of the uncorrected standard gamble score and table entries are corrected scores, e.g., the 607 
corrected utility for a standard gamble of 0.15 is 0.123 (underlined). 608 
 609 
 610 
      0.00    0.01    0.02    0.03    0.04    0.05    0.06    0.07    0.08    0.09 611 
0.0   0.000   0.025   0.038   0.048   0.057   0.064   0.072   0.078   0.085   0.091 612 
0.1   0.097   0.102   0.108   0.113   0.118   0.123   0.128   0.133   0.138   0.143 613 
0.2   0.148   0.152   0.157   0.162   0.166   0.171   0.176   0.180   0.185   0.189 614 
0.3   0.194   0.199   0.203   0.208   0.213   0.217   0.222   0.227   0.231   0.236 615 
0.4   0.241   0.246   0.251   0.256   0.261   0.266   0.271   0.276   0.281   0.286 616 
0.5   0.292   0.297   0.303   0.308   0.314   0.320   0.325   0.331   0.337   0.343  617 
0.6   0.350   0.356   0.363   0.369   0.376   0.383   0.390   0.397   0.405   0.412 618 
0.7   0.420   0.428   0.436   0.445   0.454   0.463   0.472   0.481   0.491   0.502 619 
0.8   0.512   0.523   0.535   0.547   0.560   0.573   0.587   0.601   0.617   0.633 620 
0.9   0.650   0.669   0.689   0.710   0.734   0.760   0.789   0.822   0.861   0.911621 
 622 
Figure 1.  Observed rating responses for a hypothetical health state with “context free” value of 623 
0.40 presented in four between-subject contexts: Restricted stimulus range (C1), broad stimulus 624 
range (C2), positively skewed stimulus set (C3), and negatively skewed stimulus set (C4).  The left 625 
panel shows a range effect on observed rating response (C1 versus C2), the right panel shows a 626 
frequency effect on observed rating response (C3 versus C4). 627 
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Figure 2.  Plot of RS and TTO difference score effect sizes and confidence intervals for 19 630 
studies. 631 
 632 
Effect Size
-1.5 -1.0 -0.5 0.0 0.5
Tsevat et al. (1996) [  ]
Read et al. (1984) [  ]
Bosch et al. (1998) [  ]
Torrance et al. (1976) [  ]
Richardson (1991) [  ]
Elkin et al. (2004) [  ]
Merlino et al. (2001) [  ]
Nuemann et al. (2000) [  ]
Mackeigan et al. (1999) [  ]
Richardson et al. 1996) [  ]
Sculpher et al. (1996) [  ]
Jonsson et al. (1991) [  ]
Sanderson et al. (2004) [  ]
Bosch et al. (2000) [  ]
Ackerman et al. (1998) [  ]
Krabbe et al. (1997) [  ]
Zug et al. (1995) [  ]
Daly et al. (1993) [  ]
Schw artzinger et al. (2003) [  ]
Summary
Study (year) [reference] RS < TTO RS > TTO
St
ud
y 
Re
fe
re
nc
e
 633 
Doctor et al. Health Utility Bias   27 
 
Figure 2.  Plot of RS and SG difference score effect sizes and confidence intervals for 16 studies. 634 
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